Protalix BioTherapeutics, Inc. (NYSE: PLX) announced 2025 financial and operational results in a March 18 th, 2026, press release and Form 10-K filing. The reports were followed by a conference call, ...

The European Commission approved a new dosing regimen for EFrio, enhancing treatment options for Fabry disease patients in the EU. Protalix BioTherapeutics Inc (PLX) received a EUR25 million milestone ...

PLX-200 is an orally available compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. The company stated that gemfibrozil’s ability to cross the blood-brain barrier has been ...

Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX’s growth thesis centers on Elfabrio’s EU approval and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's the ...

Protalix has a price-to-earnings (P/E) ratio of 32.200 (TTM). This compares to an industry average of 20.277. What is Protalix’s price-to-sales ratio? The P/S ratio for Protalix is currently 2.510 ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Abstract: Detector systems in modern nuclear and particle physics experiments must handle numerous channels and high data throughput. Furthermore, the requirements for trigger systems have become ...